Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PC
Processa Pharmaceuticals, Inc. Common
PCSA
Volume
21.49K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PC
PCSA
PC
Processa Pharmaceuticals, Inc. Common
PCSA
News
·
Gastroparesis Market Poised for Extraordinary Growth at a 21.9% CAGR in the US by 2034 Due to the Launch of Novel MoAs Such as NK-1R Antagonists, 5-HT4 Receptor Agonists, D2 Receptor Antagonists, and Others | DelveInsight
Mkt Cap
$4.7M
Volume
21.49K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
Gastroparesis Market Poised for Extraordinary Growth at a 21.9% CAGR in the US by 2034 Due to the Launch of Novel MoAs Such as NK-1R Antagonists, 5-HT4 Receptor Agonists, D2 Receptor Antagonists, and Others | DelveInsight
The gastroparesis market is expected to grow significantly at a 21.9% CAGR by 2034, driven by novel therapeutic approaches targeting different receptor mechanisms and addressing current treatment limitations.
GlobeNewswire Inc. · Oct 27, 2025
Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight?
Processa Pharmaceuticals saw a significant stock price increase after initiating a Phase 2 clinical trial for next-generation capecitabine (NGC-Cap) as a potential treatment for advanced breast cancer, with interim results expected in mid-2025.
Benzinga · Oct 8, 2025
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
Processa Pharmaceuticals announced the acceptance of three abstracts for the 2025 ASCO Annual Meeting, highlighting its pipeline of Next Generation Cancer (NGC) drug candidates, including PCS6422 (NGC-Cap) and PCS11T (NGC-Iri).
GlobeNewswire Inc. · May 30, 2025
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
Processa Pharmaceuticals, a clinical-stage pharmaceutical company, announced its participation in the 2025 BIO CEO & Investor Conference, where it will present a corporate overview and hold one-on-one meetings with investors.
GlobeNewswire Inc. · Feb 7, 2025
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals, a clinical-stage pharmaceutical company, announced the closing of a $5 million public offering. The offering included the sale of common stock and warrants to institutional investors and company insiders.
GlobeNewswire Inc. · Jan 30, 2025
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals, a clinical-stage pharmaceutical company, announced the pricing of a $5 million public offering, with participation from the company's CEO, board members, and existing institutional investors.
GlobeNewswire Inc. · Jan 28, 2025
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
Processa Pharmaceuticals, a clinical-stage pharmaceutical company, announces its participation in the H.C. Wainwright 26th Annual Global Investment Conference and the European Society for Medical Oncology (ESMO) Congress 2024 in September 2024.
GlobeNewswire Inc. · Sep 3, 2024
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months
GlobeNewswire Inc. · Jun 11, 2024
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that management will be participating in the EF Hutton Annual Global Conference being held May 15, 2024 at The Plaza Hotel in New York City. Management will be holding one-on-one meetings with investors.
GlobeNewswire Inc. · May 6, 2024
Spotting Penny Stocks Uptrends, 3 Top Tips
Here's how to spot penny stocks with potential uptrends The post Spotting Penny Stocks Uptrends, 3 Top Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks · Apr 26, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PC
PCSA
Processa Pharmaceuticals, Inc. Common
Buy
Sell
Market
Limit
Soon
PCSA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PCSA yet.
Related Tickers
Earnings